Cancer
INDICATION: Acute myelogenous leukemia (AML)
In vitro, cell culture and mouse studies identified two USP10 inhibitors that could help treat AML harboring internal tandem duplication (ITD) mutations in FLT3. Screening of deubiquitinating enzyme (DUB) inhibitors in a cell-based assay of ITD-mutant